Shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus target price of $27.00 for the company and are anticipating that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Verrica Pharmaceuticals an industry rank of 97 out of 256 based on the ratings given to related companies.
VRCA has been the topic of a number of recent analyst reports. HC Wainwright increased their price target on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 11th.
Verrica Pharmaceuticals stock traded up $1.46 during trading hours on Monday, hitting $12.37. The company had a trading volume of 96,465 shares, compared to its average volume of 54,620. The company has a market cap of $318.01 million and a price-to-earnings ratio of -8.77. Verrica Pharmaceuticals has a 1 year low of $6.44 and a 1 year high of $18.58. The business’s 50-day simple moving average is $10.45.
Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.02). As a group, equities analysts expect that Verrica Pharmaceuticals will post -1.25 earnings per share for the current fiscal year.
In related news, major shareholder Matt Davidson sold 3,356 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $9.21, for a total transaction of $30,908.76. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 134,034 shares of company stock worth $1,409,408 over the last three months. 40.20% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in VRCA. Asymmetry Capital Management L.P. lifted its holdings in Verrica Pharmaceuticals by 12.0% during the first quarter. Asymmetry Capital Management L.P. now owns 70,458 shares of the company’s stock valued at $762,000 after purchasing an additional 7,576 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth about $28,000. BlackRock Inc. lifted its stake in shares of Verrica Pharmaceuticals by 4.9% in the fourth quarter. BlackRock Inc. now owns 267,665 shares of the company’s stock worth $2,182,000 after buying an additional 12,537 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Verrica Pharmaceuticals in the first quarter worth about $111,000. Finally, Northern Trust Corp lifted its stake in shares of Verrica Pharmaceuticals by 7.5% in the fourth quarter. Northern Trust Corp now owns 67,028 shares of the company’s stock worth $546,000 after buying an additional 4,689 shares in the last quarter. 34.31% of the stock is currently owned by hedge funds and other institutional investors.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Featured Story: Total Return
Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.